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The equine herpesvirus 1 (EHV-1) immediate-early (IE) phosphoprotein is essential for the activation of transcription from
viral early and late promoters and regulates transcription from its own promoter. The IE protein of 1487 amino acids contains
a serine-rich tract (SRT) between residues 181 and 220. Deletion of the SRT decreased transactivation activity of the IE
protein. Previous results from investigation of the ICP4 protein, the IE homolog of herpes simplex virus 1 (HSV-1), revealed
that a domain containing a serine-rich tract interacts with EAP (Epstein–Barr virus-encoded small nuclear RNA-associated
protein), a 15-kDa nucleolar-ribosomal protein (R. Leopardi, and B. Roizman, Proc. Natl. Acad. Sci. USA 93, 4572–4576, 1996).
DNA binding assays revealed that (i) glutathione S-transferase (GST)-EAP disrupted the binding of HSV-1 ICP4 to its cognate
DNA in a dose-dependent manner, (ii) GST-EAP interacted with the EHV-1 IE protein, but did not disrupt its binding to its
cognate site in viral DNA. GST-pulldown assays indicated that the SRT of the IE protein is required for physical interaction
with EAP. The IE protein and EAP colocalized in the cytoplasm of the infected equine ETCC cells at late times of the infection
cycle. This latter finding may be important in EHV-1 gene regulation since late viral gene expression is greatly influenced by
the EICP0 trans-activator protein whose function is antagonized by the IE protein. © 2001 Academic Press
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pINTRODUCTION
The alphaherpesvirus equine herpesvirus 1 (EHV-1) is
a major pathogen of equines, causing respiratory dis-
ease, neurological disorders, and spontaneous abor-
tions in pregnant mares (Allen and Bryans, 1986;
O’Callaghan and Osterrieder, 1999). The EHV-1 genome,
which has been sequenced in its entirety, is a two-
isomer structure containing at least 72 unique genes and
six diploid genes (Breeden et al., 1992; Grundy et al.,
989; Harty and O’Callaghan, 1991; Henry et al., 1981;
olden et al., 1992a; Ruyechan et al., 1982; Telford et al.,
992; Whalley et al., 1981). During a productive lytic
nfection, the genes of EHV-1 are coordinately expressed
nd temporally regulated in an immediate-early (IE),
arly (E), and late (L) fashion (Gray et al., 1987a, 1987b).
HV-1 EICP22 (previously named IR4; ICP22 homolog;
olden et al., 1992a), EICP27 (previously named UL3;
CP27 homolog; Zhao et al., 1992), and ICP0 (Bowles et
l., 1998) are regulated as E genes, in contrast to the
ase for herpes simplex virus type 1 (HSV-1), in which the
omologs of these three regulatory genes are members
f the IE gene family (Anderson et al., 1980; Honess and
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173oizman, 1974; Jones et al., 1977; Mackem and Roizman,
981; Preston et al., 1978; Watson et al., 1979).
The IE gene (IR1) of EHV-1 is essential for replication
Garko-Buczynski et al., 1998), lies within each of the two
nverted repeats, and encodes a 1487 amino acid (aa)
olypeptide (IE) (Grundy et al., 1989). Transient transfec-
ion experiments demonstrated that the IE gene product
rans-activates EHV-1 and heterologous viral promoters,
rans-represses its own expression, and acts synergisti-
ally with the EICP22 and EICP27 proteins to trans-
ctivate E and L promoters (Holden et al., 1995; Mat-
umura et al., 1993; Smith et al., 1992, 1993; Zhao et al.,
995). The EHV-1 IE and EICP0 proteins are potent trans-
ctivators of EHV-1 promoters (Bowles et al., 1998; Smith
t al., 1992). However, when used together, they did not
unction synergistically (Bowles et al., 2000). Residues
22 to 597 (region 2) of the IE protein are sufficient for its
equence-specific DNA binding to nucleotides at posi-
ion at 211 to 114 relative to the transcription initiation
ite (11), which overlap the transcription initiation site in
he EHV-1 IE gene (Kim et al., 1995). The IE protein also
inds weakly to sequences in the E and L promoters that
ontain a degenerate version of the consensus binding
equence 59-ATCGT-39 (Kim et al., 1995). The EHV-1
ICP22 protein increased the in vitro DNA binding activ-
ty of the IE protein for sequences in the IE, E, and L
romoters (Kim et al., 1997). The EICP22 protein restored
artially the DNA binding activity of the IEQ495E mutant
hat by itself did not bind to DNA, indicating that the
0042-6822/01 $35.00
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174 KIM ET AL.EICP22 protein cooperates with IE protein to increase or
stabilize the IE DNA binding activity (Kim et al., 1997). A
potent transcriptional activation domain lies within the
first 89 aa residues of the IE protein (Buczynski et al.,
1999; Smith et al., 1994), and aa 963 to 970 are necessary
for nuclear localization of the truncated IE polypeptides
(Smith et al., 1995). The IE protein binds to the transcrip-
tion initiation site of the gK promoter sequences, thereby
repressing its transcription (Kim et al., 1999).
Figure 1 presents a comparison of the amino acids
sequence of the serine-rich and acidic region of EHV-1 IE
protein, HSV-1 ICP4, varicella-zoster virus (VZV) ORF62
protein, and pseudorabies virus (PRV) IE180, showing
that the serine-rich regions of alphaherpesvirus are very
similar. The serine-rich region is followed by five to
seven acidic residues. The region within aa 181 to 220 of
the IE protein contains two serine-rich and acidic re-
gions. The serine-rich region of HSV-1 ICP4 is well con-
served and has been shown to be important for the
induction of early and leaky late gene expression, par-
ticularly in an ICP4 mutant lacking the C-terminal se-
quences (Paterson and Everett, 1988; Sephard et al.,
1989). Residues in this region are potential sites for
phosphorylation and are involved in the functions of ICP4
(Xia et al., 1996).
Epstein–Barr virus (EBV), an oncogenic herpesvirus,
encodes two small RNAs (EBERs) that are expressed at
high levels during latent transformation of human B lym-
phocytes (Lerner et al., 1981; van Santen et al., 1981).
EBERs are associated with EAP (EBER-associated pro-
tein), which is a 15-kDa nucleolar-ribosomal protein (Toc-
zyski and Steitz, 1993) later found to be L22, a ribosomal
component (Toczyski et al., 1994). In EBV-infected human
B lymphocytes, the EBER1 binds to and relocalizes ribo-
FIG. 1. Comparison of the amino acid sequences of the serine-rich
nd acidic regions of EHV-1 IE protein, HSV-1 ICP4, VZV ORF62 protein,
nd PRV IE180. Top diagram represents the 1,487-amino-acid IE protein
f EHV-1. TAD, acidic transcriptional activation domain; SRT, serine-rich
ract; NLS, nuclear localization sequences. The numbers refer to the
umber of amino acids from the N-terminus of each protein. The
similarity between the sequences, with the run of serines followed by
five to seven acidic residues, is obvious.somal protein L22 that normally resides in the nucleolus
but is also associated with ribosomes (Toczyski et al.,1994). Recent investigation (Dobbelstein and Shenk,
1995) of the RNA-binding properties of EAP suggests that
it can bind to 28S ribosomal RNA in a highly conserved
stem-loop structure resembling the binding site on
EBERs. The serine-rich tract (SRT) of the HSV-1 ICP4 may
interact with EAP (Leopardi and Roizman, 1996). Early in
infection, ICP4 was dispersed throughout the nucleo-
plasm, whereas EAP was localized to the nucleolus; late
in infection, EAP was translocated from the nucleolus
and colocalized with ICP4 in small and dense nuclear
structures (Leopardi and Roizman, 1996). In gel shift
assay, glutathione S-transferase (GST)-EAP disrupted the
binding of ICP4 to its cognate DNA in a dose-dependent
manner (Leopardi and Roizman, 1996). These results
suggested that the translocation of EAP from the nucle-
olus to nucleoplasm is a viral function and that EAP plays
a role in the regulatory functions expressed by ICP4.
We report here that EAP interacts with the EHV-1 IE
protein, that the interaction does not displace the binding
of the IE protein to its cognate DNA site, and that late in
infection, EAP and the IE protein colocalize in the cyto-
plasm of infected equine ETCC cells. The significance of
this observation in the regulation of EHV-1 gene pro-
gramming is discussed.
RESULTS
The EHV-1 IE protein interacts with EAP
The EHV-1 IE protein contains a serine-rich tract
between amino acids 181 and 220 (Fig. 1). To deter-
mine whether the IE protein interacts with EAP, GST-
pulldown assays were performed with the GST-EAP
protein and EHV-1-infected RK cell nuclear extracts.
The GST-EAP protein was expressed and purified from
E. coli BL21(DE3) as a stable form (data not shown). In
GST-pulldown assays, the IE protein of the EHV-1-
infected RK cell nuclear extracts was coprecipitated
with the GST-EAP protein (Fig. 2A, lane 5), but not with
GST protein (Fig. 2A, lane 4). The fast migrating bands
may be proteolytic cleavage products (Fig. 2A, lanes 3
and 5). These results indicated that EAP interacts with
the IE protein. The GST-EAP protein also coprecipi-
tated the HSV-1 ICP4 protein (Fig. 2B, lane 5), indicat-
ing that EAP interacts with the ICP4 protein, consistent
with the finding of Leopardi and Roizman (1996), who
showed that the HSV-1 ICP4 protein interacts with EAP
in a yeast two-hybrid system. To confirm these results,
in vitro transcription/translation vectors that encode
the intact and mutant forms of the IE protein were
generated (Fig. 3A), and GST-pulldown assays were
performed with equal amounts of each in vitro tran-
scribed/translated IE proteins protein (Fig. 3B). The
full-length IE protein was coprecipitated with the GST-
EAP protein (Fig. 3B, lane 1), but not with GST protein
(Fig. 3B, lane 2). The IED644/824 protein was also
coprecipitated with the GST-EAP protein (Fig. 3B, lane
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175THE EHV-1 IE PROTEIN INTERACTS WITH EAP3), but not with GST protein (Fig. 3B, lane 4), indicating
that IE protein residues mapping at aa 644 to 824 (part
of human TFIIB binding domain of the IE protein, Jang
and O’Callaghan, unpublished data) are not important
for the physical interaction of the IE protein with the
EAP. When the IE mutant proteins IEDSRT1, IEDSRT2,
nd IEDSRT3D644/824 were incubated with the GST-
AP protein, only small amounts of each of the SRT
eletion mutant proteins interacted with the GST-EAP
rotein (Fig. 3B, lanes 5, 7, and 9, respectively). These
FIG. 2. GST-pulldown assay with EHV-1-infected cell nuclear extracts
(A) and HSV-1-infected cell nuclear extracts (B). Equal amounts of each
nuclear extract were preincubated with the GST (lanes 4 and 6) and
GST-EAP (lanes 5 and 7) proteins and preincubated with glutathione
Sepharose 4B beads. Lanes 1 (RK cell nuclear extract) and 2 (EHV-1-
infected RK cell nuclear extract) contain negative and positive controls,
respectively. The precipitates were electrophoresed through a SDS–6%
(A) or 10% (B) PAGE gels, blotted to nitrocellulose filters, and probed
with the anti-IE monoclonal antibody A1.4 (A) or the anti-ICP4 mono-
clonal antibody 58s (B). The IE and ICP4 protein bands are indicated
with arrows (a and c, respectively). The band (b) that interacted with
GST-EAP is indicated with an arrow. The numbers on the left represent
molecular mass standards (Bethesda Research Laboratories) in kilo-
daltons.esults suggest that the EAP protein interacts with the
omain of the SRT region of the IE protein.
r
mRT deletion of the IE protein decreases the CAT
ctivity of the IE protein
To investigate whether the SRT region affects the func-
ion of the IE protein, SRT deletion mutants of the IE
rotein were expressed in mouse fibroblast LM cells and
hen expression was confirmed by Western blot (Fig. 4A).
he IE protein expressed under the control of the SV40
romoter exhibited the same pattern as that present in
n EHV-1-infected nuclear extract (compare 4A lane 4
ith 4A lane 2). The SRT deletion mutants of the IE
rotein (IEDSRT1 and IEDSRT2) migrated in the SDS–
AGE as predicted by their sizes (Fig. 4A, lanes 5 and 6,
espectively). Transient transfection assays were per-
ormed with the SRT deletion mutants of the IE protein to
scertain if it could trans-activate an EHV-1 promoter
FIG. 3. GST-pulldown assays with in vitro transcribed/translated IE
nd mutant forms of it. (A) Schematic diagram of SRT deletion mutants
f the IE protein. Top diagram represents the 1,487-amino-acid IE
rotein of EHV-1. TAD, acidic transcriptional activation domain; SRT,
erine-rich tract; NLS, nuclear localization sequences. The numbers
efer to the number of amino acids from the N-terminus of each protein.
B) Plasmids expressing the IE deletion mutants shown in A were in
itro transcribed–translated and radiolabeled with [35S]methionine as
escribed under Materials and Methods. Equal amounts of each ra-
iolabeled species were preincubated with the GST (lanes 2, 4, 6, 8, 10)
nd GST-EAP (lanes 1, 3, 5, 7, 9) proteins and precipitated with gluta-
hione Sepharose 4B beads. The precipitated pellets were electropho-
esed through a SDS–6% PAGE gel. The numbers on the left represent
olecular mass standards in kilodaltons.
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176 KIM ET AL.linked to the CAT reporter gene. The EICP22 protein by
itself did not transactivate the EHV-1 early thymidine
kinase (TK) promoter (Fig. 4B, Bar 2), but acted syner-
gistically with the IE protein to trans-activate the TK
romoter (Fig. 4B, Bar 4). This result is consistent with
ur previous findings (Holden et al., 1995). The dele-
ion of IE aa residues 182 to 249 (pSVIEDSRT1) (Fig.
B, bar 5) decreased the CAT activity to 50% of that of
ild type (Fig. 4B, Bar 3). The deletion of IE aa 89 to
42 (pSVIEDSRT2) decreased the CAT activity to only
0% (Fig. 4B, Bar 7) of that of the full-length IE protein
Fig. 4B, Bar 3). Cotransfection of pSVIE and pcDR4
EICP22 expression vector) resulted in a fourfold in-
rease in CAT activity (Fig. 4B, Bar 4). When the pcDR4
lasmid was cotransfected with the pSVIEDSRT1 and
SVIEDSRT2, two- and threefold increases in CAT ac-
ivity were observed (Fig. 4B, Bars 6 and 8, respec-
ively). Similar results were observed with the EHV-1
ate IR5 promoter reporter plasmid pIR5-CAT (Fig. 4C),
ndicating that the SRT deletion of the IE protein did
FIG. 4. SRT deletion of the IE protein decreases its trans-activation
NE, EHV-1 KyA virus-infected LM cell nuclear extract; NE, mock-infected
(B) and (C) CAT assays with the SRT deletion mutants of the IE protein
IR5-CAT) and 0.3 pmol of effector plasmids (pSVIE, pSVIEDSRT1, and pS
error bars show standard deviations.ot affect significantly the synergistic effect of the IE
nd EICP22 proteins. tST-EAP interacts with the IE protein without
isrupting the binding of the IE protein to its
ognate site in DNA
To confirm that EAP interacts with the IE protein, gel
hift assays were performed with EHV-1-infected RK cell
uclear extracts and the radiolabeled probe of IE oligo-
ucleotide harboring sequences at 213 to 115. In the
HV-1-infected RK cell nuclear extracts, an additional
omplex was seen (Fig. 5A, lane 2) as compared to the
ock-infected (Fig. 5A, lane 1). The IE protein–DNA com-
lexes were supershifted by the addition of anti-IE-spe-
ific MAb A1.4 (Fig. 5A, lane 3) and were completely
ompeted by the addition of unlabeled excess competi-
or, the 28-bp oligonucleotide IE1 (Fig. 5A, lane 4), which
ontains the EHV-1 IE DNA sequences from 213 to 115.
his finding indicated that the IE protein of nuclear ex-
racts prepared from EHV-1-infected RK cells binds spe-
ifically to the IE promoter DNA. Some faster-migrating
ands (under band a) may be cellular or viral proteins–
NA complexes due to nonspecific interaction.
(A) Western blot of the SRT deletion mutants of the IE protein. EHV-1
ll nuclear extract; pSVIE NE, pSVIE-transfected LM cell nuclear extract.
ells were transfected with 2.0 pmol of reporter plasmids (TK-CAT and
RT2). Each transfection was performed in triplicate. Data are averages;activity.
LM ce
. LM cTo investigate whether the EAP disrupts the binding of
he IE protein to its cognate DNA, additional gel shift assays
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177THE EHV-1 IE PROTEIN INTERACTS WITH EAPwere performed in the presence of GST-EAP. Interestingly,
addition of GST-EAP did not disrupt the binding of the
EHV-1 IE protein to its cognate DNA; on the contrary, the
IE-DNA complexes were additionally shifted up by the ad-
dition of GST-EAP (Fig. 5B, lane 2) but not by GST protein
(Fig. 5B, lane 6). Also, GST-EAP increased the in vitro DNA
inding activity of the IE protein (Fig. 5B, lane 2). GST-EAP
y itself did not bind to the IE promoter DNA (data not
hown). The IE-DNA-EAP complexes were supershifted by
he addition of either the anti-IE-specific MAb or the anti-
ST-specific Ab (Fig. 5B, lanes 4 and 5, respectively). The
E-DNA-EAP complexes were not supershifted by the addi-
ion of EAP MAb T3 (data not shown), indicating that the
pitope of the EAP for T3 may not be exposed due to the
nteraction of EAP with the IE protein. These results indi-
ated that EAP may interact with the IE protein, but does not
ffect the DNA binding ability of the IE protein. Previous
esults for HSV-1 by Leopardi and Roizman (1996) showed
hat GST-EAP disrupted the binding of ICP4 to DNA in a
ose-dependent manner. These results indicate that EAP
nteracts with the IE protein without steric hindrance of
NA binding mediated by the IE protein.
he ICP4-DNA complexes are not completely
isrupted by the addition of GST-EAP
FIG. 5. Gel shift assay with EHV-1-infected cell nuclear extracts. The
radiolabeled probe, IE1 (position 213 to 115), was incubated with 1 mg
of nuclear extracts from RK (A, lane 1) and EHV-1-infected RK cells (A,
lanes 2 to 4; B). NE, nuclear extracts; 2, no protein added; A1.4,
monoclonal antibody to the IE protein (Caughman, 1995); a, the IE
protein 1 DNA; b, the IE protein 1 DNA 1 a-IE MAb. In lanes 2, 4, 5,
, and 8, 200 ng of GST-EAP were employed. In lane 6, the amount of
ST employed was 400 ng.Previous results from investigation of HSV-1 ICP4
Leopardi and Roizman, 1996) revealed that a domaincontaining a SRT may interact with EAP and that GST-
EAP disrupted the binding of ICP4 to its cognate DNA in
a dose-dependent manner. To investigate whether EAP
interacts with ICP4, gel shift assays were performed with
HSV-1-infected Vero cell nuclear extracts. In the HSV-1-
infected Vero cell nuclear extracts, an additional complex
was also seen (Fig. 6A, lane 2). The ICP4 protein–DNA
complexes were supershifted by the addition of ICP4-
specific MAb 58s (Fig. 6A, lane 3) and were completely
competed by the addition of unlabeled excess competi-
tor, the 34-bp oligonucleotide ICP4 (Fig. 6A, lane 4),
which contains the HSV-1 ICP4 DNA sequences from
211 to 123. These results indicated that the ICP4 pro-
tein in nuclear extracts prepared from HSV-1-infected
Vero cells binds specifically to the ICP4 promoter DNA.
The addition of increasing amounts of GST-EAP gradu-
ally disrupted the binding of ICP4 to its cognate DNA.
This finding is consistent with that previously reported
(Leopardi and Roizman, 1996). Importantly, high concen-
trations of GST alone had no effect on the ICP4–DNA
complex (Fig. 6B, lanes 2 to 4). However, the ICP4–DNA
complexes were not completely disrupted by the addition
of GST-EAP under the conditions employed (Fig. 6B,
lanes 6 to 9). To address this observation further, the
ICP4-DNA complexes were shifted up by the addition of
the high concentration of GST-EAP (Fig. 6C, lanes 5 and
6; 6D, lanes 3 and 4; 6E, lane 2). The ICP4-DNA-ICP4
MAb complexes were additionally shifted up by the ad-
dition of GST-EAP (compare 6E lane 4 with 6E lane 3).
When 200 ng of GST-EAP was added to the DNA binding
mixture, the ICP4-DNA complexes and ICP4-DNA-EAP
complexes were seen (Fig. 6C, lanes 5; 6D, lanes 3 and
4). The two bands were supershifted by the addition of
the ICP4-specific MAb (Fig. 6D, lane 6), indicating that
the shifted band (indicated as b) is the ICP4-DNA-EAP
complexes. In addition, antibody to EAP also shifted the
band, indicating its presence in the complex (data not
shown). These results confirmed the finding of Leopardi
and Roizman that the ICP4 protein interacts with the
GST-EAP and revealed that the interaction of ICP4 with
GST-EAP affects the DNA binding activity of the ICP4 to
its cognate DNA.
The IE protein and EAP colocalize in the cytoplasm
of the infected equine ETCC cells at very late
times of infection
To determine whether the IE protein and EAP colo-
calize in the infected cells, laser confocal microscopic
studies were performed with an EAP-specific mono-
clonal antibody and a polyclonal antibody to the IE
protein in ETCC cells. In equine ETCC cells, EAP is
found in the nucleolus of uninfected cells (Fig. 7A),
whereas the IE protein is distributed throughout the
nucleus (Fig. 7B), and its distribution changes during
the course of infection (Fig. 7C). Early in infection (4 to
and 40
lanes 2
178 KIM ET AL.7 h postinfection), the IE protein was dispersed
throughout the nucleus but was excluded from struc-
tures containing aggregates of EAP and resembling
the nucleoli of uninfected cells (Fig. 7B). Late in infec-
tion (8 to 16 h postinfection), most of the IE protein and
EAP did not colocalize in the nucleus of the infected
ETCC cells, but small amounts of the two protein
appeared to be tightly aggregated in small and dense
nuclear structures within the nucleoplasm (Fig. 7C).
Interestingly, some of the IE protein was localized in
FIG. 6. Gel shift assay with HSV-1-infected cell nuclear extracts. T
incubated with 1 mg of nuclear extracts from HSV-1-infected Vero cells
58s; a, ICP4 1 DNA; b, ICP4 1 DNA 1 EAP; c, ICP4 1 DNA 1 a-ICP4 M
of protein added, at 5 ng (lanes 2 and 6), 80 ng (lanes 3 and 7), 200 ng (l
added, at 5 ng (lane 2), 20 ng (lane 3), 60 ng (lane 4), 150 ng (lane 5),
at 40 ng (lane 2), 200 ng (lanes 3 and 6), 300 ng (lane 4). (E) 400 ng (the cytoplasm of infected ETCC cells at 13 h after
infection (data not shown). Unexpectedly, colocaliza-tion of the IE protein and EAP in the cytoplasm of some
infected ETCC cells was observed at late times after
infection (Figs. 7D–7I). The IE protein–EAP complexes
showed a perinuclear pattern (Figs. 7F and 7I). In
rabbit RK-13 and mouse L-M cells, the IE and EAP
proteins did not colocalize in the nucleus of the in-
fected cells (data not shown). As mentioned above, the
IE protein is relocalized to the cytoplasm in dense
structures in equine ETCC cells at late times after
infection, suggesting that EAP by itself did not relocal-
iolabeled probe, ICP4 (position 211 to 123 of the ICP4 gene), was
uclear extracts; 2, no protein added; a monoclonal antibody to ICP4,
ICP4 1 DNA 1 a-ICP4 MAb 1 EAP. (B) triangles, increasing amounts
and 500 ng (lanes 4 and 9). (C) Triangle, increasing amounts of protein
0 ng (lane 6). (D) Trapezoid, increasing amounts of the protein added,
and 4).he rad
. NE, n
Ab; d,
ane 8),ize the IE protein and that some other factor(s) played
a role in the relocalization of the IE protein.
(red)
179THE EHV-1 IE PROTEIN INTERACTS WITH EAPDISCUSSION
In this paper, we show that the EHV-1 IE protein
interacts and colocalizes with EAP, a cellular protein that
shuttles from the nucleus to the ribosomes. Previous
results from investigation of HSV-1 ICP4 revealed that
the serine-rich region (SRT) of the immediate-early ICP4
protein interacts with EAP and that late in infection, EAP
was translocated from the nucleolus and colocalized
with ICP4 in small and dense nuclear structures (Leo-
pardi and Roizman, 1996). These results suggested that
this translocation of EAP is a viral function and that EAP
plays a role in the regulatory functions expressed by
ICP4. At immediate-early and early times of infection, the
EHV-1 IE protein is localized in the nucleus of infected
cells in human HeLa, rabbit RK-13, and mouse L-M cells
(data not shown). Late in infection, the IE protein and
EAP colocalized in the cytoplasm of some infected
FIG. 7. Photomicrographs of infected equine ETCC cultures. EHV-1 (s
(D–I) postinfection. The cells were reacted first with a 1:100 dilution of
monoclonal antibody to EAP in PBS/1% BSA for 3 h. After rinsing
TRITC-conjugated anti-rabbit IgG for 1 h and examined under a confoc
and EAP (green). D, G, F, and H show the single staining patterns of IE
L, late pattern (7 to 16 h).equine ETCC cells as tightly aggregated, small and
dense nuclear structures. The colocalization of the IEprotein and EAP observed by confocal microscope sup-
ports the biochemical and genetic evidence for the in-
teraction of these two proteins. The late and cell-specific
function(s) required for the two proteins to colocalize
may involve (i) a posttranslational modification of the IE
protein that renders it capable of binding EAP, (ii) inter-
action of a cellular gene product with EAP and/or the IE
protein, and/or (iii) interaction of another viral gene prod-
uct with EAP and/or the IE protein.
The finding that the IE protein and EAP interact in the
cytoplasm at late times postinfection may reflect an im-
portant aspect of EHV-1 gene regulation. Our recent
studies indicate that late viral gene expression is greatly
influenced by the EICP0 protein, a potent and indepen-
dent trans-activator of late viral promoters (Bowles et al.,
1998; Kim et al., 1999). This early regulatory protein has
an antagonistic relationship with the IE protein such that
yA)-infected ETCC equine cells were fixed at 4 h (B), 9 h (C), and 13 h
clonal antibody to IE (antipeptide Ab 925-943) and a 1:20 dilution of a
ells were reacted with an FITC-conjugated anti-mouse IgG and a
scope. F and I show the merged image of staining pattern for IE (red)
and EAP (green). A and D, Uninfected cells. E, early pattern (4 to 6 h);train K
a poly
, the c
al microat high ratios of the concentration of the IE protein to that
of the EICP0 protein, late gene expression is reduced
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180 KIM ET AL.significantly (Bowles et al., 1998, 2000; Kim et al., 1999).
Thus, the cytoplasmic retention of the IE protein at late
times of the infection cycle by its interaction with EAP
may foster late gene expression.
The results of Leopardi and Roizman (1996) showed
that the serine-rich tract of ICP4 interacts with EAP and
that this interaction disrupted the binding of ICP4 protein
to its cognate DNA in a dose-dependent manner. Our
results support these findings. EAP also interacts with
the IE protein but without steric hindrance of the DNA
binding activity of the IE protein. These results indicated
that EAP interacted with the IE protein and ICP4, but
affects differently the DNA binding ability of these two
alphaherpesviral regulatory proteins.
In this study, human EAP (Toczyski and Steitz, 1991)
was used for the GST-pulldown and gel shift assays. The
human EAP interacted with the IE protein, and the MAb
prepared to human EAP also reacted well with EAP in the
equine ETCC cells. This was not unexpected since hu-
man EAP exhibits an extremely high degree of similarity
with the sea urchin 217 protein, a homolog of human EAP
(Toczyski and Steitz, 1991). The close relationship be-
tween the human and sea urchin EAP would suggest
that the EAP of the equine and the human also are highly
conserved.
Experiments in our laboratory have demonstrated that
the IE protein acts synergistically with the EICP22 protein
to trans-activate the E and L promoters (Holden et al.,
995), specifically its in vitro DNA binding activity for
equences in the IE, E, and L promoters is greatly in-
reased by the EICP22 protein (Kim et al., 1997). The
ICP22 protein physically interacts and colocalizes with
he IE protein (Derbigny et al., 2000). The findings that
eletion of the SRT domain of the IE protein affected its
rans-activation activity but did not significantly affect the
ynergistic effect of the IE and EICP22 proteins are
onsistent with our recent data on the characterization of
HV-1 mutants that harbor altered forms of the IE gene.
he SRT domain is not essential for the nuclear localiza-
ion of the IE protein; however, a mutant EHV-1 that lacks
he SRT-encoding sequence of the IE gene (KyAIEDSRT)
is not capable of replication in cell culture, indicating the
importance of the SRT for the IE protein to perform one or
more of its essential functions (Buczynski and
O’Callaghan, unpublished data). Taken together, our re-
sults allow the speculation that the interactions of the IE
protein with the EICP22 protein and EAP are important
events in EHV-1 replication. HSV-1 mutants in which the
serine-rich region (aa 143 to 210) of ICP4 is deleted
exhibit reduced viral yields and delayed E and L gene
synthesis in tissue culture, but demonstrate a total block
in replication in the trigeminal ganglia of infected mice
(Bates and DeLuca, 1998). These observations suggest
that the SRT region of ICP4 is necessary for the progres-
sion of lytic infection in neurons. Interestingly, in the
HSV-1 system, it has been shown that ICP4, ICP22, EAP,and RNA pol II colocalize with progeny viral DNA in
defined nuclear structures and that this colocalization is
dependent on the presence of functional viral protein
kinases (Leopardi et al., 1997).
The studies presented in this paper document the
interaction and colocalization of the major regulatory
protein of another alphaherpesvirinae member, EHV-1,
and the cellular EAP protein. Additional studies are in
progress to attempt to evaluate the function and signifi-
cance of these interactions and colocalization.
MATERIALS AND METHODS
Virus and cell culture
The KyA strain of EHV-1 was propagated in suspen-
sion cultures of L-M mouse fibroblasts as previously
described (Perdue et al., 1974). L-M cells were propa-
gated in suspension culture with YELP medium (Eagle’s
Minimum Essential Medium (EMEM) supplemented with
yeast extract, lactalbumin hydrolysate, peptone) contain-
ing 0.12% methyl cellulose, 100 U of penicillin per ml, 100
mg of streptomycin per ml, and 5% fetal bovine serum
(FBS). The equine transitional cell carcinoma (ETCC) and
rabbit kidney (RK-13) cells were maintained at 37°C in
complete EMEM supplemented with 100 U of penicillin
per ml, 100 mg of streptomycin per ml, nonessential
amino acids, and 5% FBS.
Plasmids
Plasmids were constructed and maintained in E. coli
HB101 by standard methods (Sambrook et al., 1989). To
construct the pSVIEDSRT1 vector, which deleted aa 182 to
248 of the IE protein, pSVIE was digested with BspEI, filled
with Klenow fragment, and inserted with an EcoRI linker
(59-CGGAATTCCG-39). To construct the pSVIEDSRT2 vec-
tor, which deleted IE aa 89 to 242, the HindIII-BamHI
fragment of pSVIE was cloned into HindIII-BamHI-
digested pUC19 to generate plasmid pUIE. The pUIE
was digested with NaeI and self-ligated to generate
plasmid pUIEDSRT2. The HindIII-BamHI fragment of
pUIEDSRT2 was cloned into HindIII-BamHI-digested
pSVIE, resulting in the pSVIEDSRT2 clone. The SRT
deletion vectors pSVIEDSRT1 and pSVIEDSRT2 were
dentified by DNA sequencing. It should be noted that
mino acids adjacent to the SRT motif per se are not
resent in the mutant proteins encoded by the two SRT
eletion constructs. The plasmid pG3IE, which contains
ull-length IE gene, has been described previously (Buc-
ynski and O’Callaghan, unpublished data). Plasmid
SVIE(1–1487) was partial- digested with NotI and self-
igated to generate plasmid pSVIED644/824. To construct
the pGEMIED644/824, the EcoRI-HindIII fragments of pS-
VIED644/824 were cloned into EcoRI-HindIII- digested
pGEM-3Z (Promega, Madison, WI). To construct the
pGEMIEDSRT1, the EcoRI-HindIII fragments of
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pGEM-3Z. To construct the pGEMIEDSRT2, the
EcoRI-HindIII fragments of pSVIEDSRT2 were cloned into
EcoRI-HindIII-digested pGEM-3Z. To construct the
pGEMIEDSRT3D644/824, pGEMIED644/824 was digested
with BspE1 and BamHI, filled with Klenow fragment, and
self-ligated the plasmid with T4 DNA ligase. The GST-EAP
expression vector (a generous gift from Dr. Joan A. Steitz,
Yale University) has been described previously (Toczyski
and Steitz, 1993).
Monoclonal antibody preparation
MAbs specific for EAP were produced as described
previously (Caughman et al., 1995) using 150 mg of pu-
rified GST-EAP for primary immunization followed by
weekly 75-mg boosts. Supernatants of the resulting hy-
bridomas were assayed by enzyme-linked immunosor-
bent assay for reactivity with the GST-EAP fusion protein
and lack of reactivity with GST protein. Reactivity was
confirmed by immunoblot analyses, and selected hybrid-
omas were cloned twice by limiting dilution and retested
for reactivity by immunoblot analysis. Cloned hybridoma
cell lines were propagated in culture, and the superna-
tants were harvested and used as the source of anti-EAP
MAbs.
Expression and purification of the GST
fusion proteins
Expression and purification of the GST fusion proteins
were carried out as previously described (Kim et al., 1995),
with slight modifications. Competent BL21(DE3)pLysE bac-
teria were transformed with expression plasmids (Studier
et al., 1990), and colonies were inoculated into 23 YT-G
medium (16 g of tryptone, 10 g of yeast extract, 5 g of NaCl
per liter, 2% (wt/vol) glucose) containing 100 mg/ml ampicil-
lin and 25 mg/ml chloramphenicol, and incubated overnight
n a shaking incubator. The culture was diluted 1:10 into 500
l fresh 23 YT medium containing 100 mg/ml ampicillin
and 34 mg/ml chloramphenicol and grown by vigorously
shaking at 37°C for 3 h. Isopropyl-b-D-thiogalactoside
(IPTG) was then added (final concentration, 0.1 mM), and
incubation was continued for 2 h. The bacteria were har-
vested by centrifugation, resuspended in 20 ml ice-cold
phosphate-buffered saline (PBS) (140 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) containing
.5 mM phenylmethyl sulfonyl fluoride (Sigma Chemical
o., St. Louis, MO), and lysed with a French press at 4°C.
he extract was centrifuged for 10 min at 12,000g. The
supernatant was incubated with 1 ml of a 50% slurry of
glutathione Sepharose 4B equilibrated with PBS at 4°C for
30 min. The matrix was washed three times by the addition
of 10 bed volumes of PBS. The GST fusion proteins were
eluted with 1 ml of glutathione elution buffer (50 mM Tris–
HCl [pH 8.0], 10 mM reduced glutathione). The solution wasmixed with a half volume of glycerol and stored in aliquots
at 270°C.
Preparation of nuclear extracts from infected cells
Nuclear extracts of infected cells were prepared by a
modification of the procedures of Paterson and Everett
(1990). RK and Vero cells were infected with EHV-1 or
HSV-1 at a MOI of 10 pfu/cell. Six hours after a 1 h
adsorption period, the cells were scraped into PBS, pel-
leted, and resuspended in 4 volumes of buffer A (10 mM
HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT,
0.5% NP40, 0.5 mM tosylphenylalanine chloromethyl ke-
tone [TPCK]). After 10 min on ice, the nuclei were pelleted
by centrifugation in a microcentrifuge at 14,000 rpm
(maximal speed) for 5 min, and the supernatant was
discarded. The nuclei were resuspended in 2 volumes of
buffer B (20 mM HEPES [pH 7.9], 25% glycerol, 0.42 M
NaCl, 1.5 mM MgCl2, 10 mM KCl, 0.2 mM EDTA, 0.5 mM
PMSF, 0.5 mM TPCK) and after 30 min on ice, the nuclear
debris was pelleted by centrifugation in a microcentri-
fuge at 14,000 rpm for 15 min. The supernatant contain-
ing the nuclear DNA-binding proteins was stored at
280°C.
In vitro transcription/translation
In vitro transcription/translation reactions to express the
IE protein and mutant form of it were performed by using
the TNT-coupled transcription/translation reticulocyte ly-
sate system as per the manufacturer’s instructions (Pro-
mega, Madison, WI). Briefly, 1.4 mg of plasmid pG3IE,
pGEMIED644/824, pGEMIEDSRT1, pGEMIEDSRT2, and
pGEMIEDSRT3D644/824 was incubated with 25 ml of rabbit
reticulocyte lysate, 1 ml of polymerase, and [35S]methionine
(40 mCi), and reaction mixtures were incubated for 2 h at
30°C and either stored at 280°C or used immediately for
GST-pulldown assays.
GST-pulldown assays
GST-pulldown assays were performed using either 20
ml of nuclear extract or 10 ml each of in vitro transcribed/
ranslated IE proteins. To these reactions, 20 ml of glu-
athione Sepharose 4B was added together with either 1
mg of GST-EAP or 2 mg of GST. Reaction volumes were
adjusted to 500 ml with NETN buffer (100 mM NaCl, 1 mM
EDTA, 20 mM Tris–HCl [pH 8.0], 0.5% Nonidet P-40
[Sigma]) and placed on a wheel at room temperature for
2 h. Beads were washed 33 with NETN buffer, resus-
pended in 20 ml of loading buffer (10% 2-mercaptoetha-
nol, 4% SDS, 20% glycerol, 0.02% [w/v] bromophenol
blue), and boiled for 4 min. The proteins were separated
by SDS–PAGE. Gels were subjected to Western blot
(Bowles et al., 1998) or were dried and allowed to expose
Kodak XAR-5 X-Omat AR film.
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Samples were boiled in 23 Laemmli samples buffer
nd separated by sodium dodecyl sulphate polyacryl-
mide gel electrophoresis (SDS-PAGE). Separated pro-
eins were transferred to nitrocellulose filters (Schleicher
nd Schuell) at 100 V for 1 h. Blots were blocked for 30
in in TBST (10 mM Tris–HCl [pH 8.0], 150 mM NaCl,
.5% Tween 20) containing 10% nonfat powdered milk
nd then incubated with a monoclonal antibody to the IE
rotein A1.4 (1:2000 dilution) or a monoclonal antibody to
CP4 58s (1:2000 dilution) in TBST for 30 min. The blots
ere washed 3 times for 10 min each in TBST and
ncubated with secondary antibody (anti-rabbit IgG[Fc]–
lkaline phosphatase conjugate [Promega]) at a dilution
f 1:4000 for an additional 30 min. The membranes were
ashed in TBST for three 10-min washes, and the pro-
eins were visualized by incubating the membranes in AP
uffer (0.1 M Tris–HCl [pH 9.5], 0.1 M NaCl, 5.0 mM
gCl2) containing nitroblue tetrazolium (0.33 mg/ml; Life
Technologies) and 5-bromo-4-chloro-3-indolylphosphate
(0.165 mg/ml; Life Technologies).
Gel shift assays
The DNA fragment harboring the IE gene promoter
from position 2144 to 161 (IE2) (Kim et al., 1995) was
nd-labeled with [a-32P]dATP. DNA binding assays
were conducted as previously described (Kim et al.,
1995). The standard DNA binding reaction mixture
contained 0.5 to 1 ng of radiolabeled DNA fragments
(2 3 104 cpm/ng), 1.5 mg of poly(dI-dC) as a nonspe-
cific competitor, and 1 to 10 ml of bacterial extract in 20
ml of DNA binding buffer (10 mM Tris–HCl [pH 7.5], 1
mM EDTA, 10 mM mercaptoethanol, 0.1% (wt/vol) 3-([3-
cholamidopropyl]dimethylammonio)-1-propanesulfon-
ate [CHAPS], 100 mM NaCl). After 30 min at 22°C, 5 ml
of loading buffer (10 mM Tris–HCl [pH 7.5], 1 mM EDTA,
10 mM mercaptoethanol, 0.1% CHAPS, 50% (vol/vol)
glycerol, 0.1% bromophenol blue) was added, and the
sample was subjected to electrophoresis at 4°C for
3 h at 200 V on a 4% polyacrylamide gel with 0.53
Tris–Borate–EDTA running buffer.
DNA transfection and chloramphenicol
acetyltransferase (CAT) assays
L-M cells seeded at 3 3 106 cells per tissue culture
dish (60 mm) in Eagle’s minimum essential medium with
5% FBS were transfected by the liposome-mediated DNA
transfection method 24 h later (Holden et al., 1995). The
pEICP22(E)-CAT plasmid was transfected in 0.45 pmol
amounts. All effector plasmids were transfected in 0.3
pmol amounts. The total amount of DNA per transfection
was adjusted to 8 mg by the addition of pUC19. After a
further 5 h, the cells were washed and refed with fresh
medium; 60 h later, total cell extracts were prepared, and
CCAT activities were assayed as described (Smith et al.,
1992).
Laser-scanning confocal microscopy
Equine transitional cell carcinoma (ETCC) cells were
seeded on two-chamber glass slides (Nalge Nunc Inter-
national, Naperville, IL) and infected with EHV-1 viruses
(KyA strain). At appropriate times after infection, cells
were fixed to the slides in methanol at 220°C for 10 min,
rehydrated in phosphate-buffered saline for 10 min,
blocked with 10% normal goat serum in PBS for 30 min,
and reacted first with a 1:100 dilution of a polyclonal
antibody to IE peptide and a 1:20 dilution of a monoclonal
antibody to EAP (T3) in PBS/1% BSA for 3 h. After rinsing,
the cells were reacted with an fluorescein isothiocyanate
(FITC)-conjugated anti-mouse IgG and a tetramethylrho-
damine-5-isocyanate (TRITC)-conjugated anti-rabbit IgG
for 1 h. Slides were mounted in 10% PBS in mount
solution (0.1% p-phenylenediamine and 90% glycerol in
PBS). Cells were examined in a laser-scanning confocal
microscope system (MRC600; Bio-Rad Laboratories) at-
tached to a Nikon Diaphot microscope (O’Callaghan et
al., 1994).
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